Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
ACS Infectious Diseases|March 20, 2025
<i>Mycobacterium tuberculosis</i> Sulfate Ester Dioxygenase Rv3406 Is Able to Inactivate the RCB18350 CompoundDeborah Recchia, Giovanni Stelitano, Anna Egorova, et al.
Journal of Medicinal Chemistry|August 20, 2021
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in <i>Mycobacterium tuberculosis</i>Lutete Peguy Khonde, Rudolf Müller, Grant A Boyle, et al.
Mbio|October 31, 2023
Transcriptional adaptation of <i>Mycobacterium tuberculosis</i> that survives prolonged multi-drug treatment in miceElizabeth A Wynn, Christian Dide-Agossou, Matthew Reichlen, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosisAllison A Bauman, Jansy P Sarathy, Firat Kaya, et al.
Antimicrobial Agents and Chemotherapy|September 30, 2024
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosisAllison A Bauman, Jansy P Sarathy, Firat Kaya, et al.
Cell|July 4, 2017
Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13Anup Aggarwal, Maloy K Parai, Nishant Shetty, et al.
Antimicrobial Agents and Chemotherapy|May 24, 2022
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective <i>In Vivo</i> with the Potential To Shorten Tuberculosis TreatmentEric L Nuermberger, Maria Santos Martínez-Martínez, Olalla Sanz, et al.
ACS Infectious Diseases|April 6, 2024
Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential LiabilitiesHelena I M Boshoff, Katherine Young, Yong-Mo Ahn, et al.
Nature Communications|October 22, 2025
The role of cytochrome bc<sub>1</sub> inhibitors in future tuberculosis treatment regimensClara Aguilar-Pérez, Anne J Lenaerts, Cristina Villellas, et al.
ACS Omega|February 1, 2021
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of <i>Mycobacterium tuberculosis</i> GrowthPeter C Ray, Margaret Huggett, Penelope A Turner, et al.
Pageof 8